| | |
Irbesartan in patients with the metabolic syndrome1
|
Irbesartan/12.5 mg HCT in patients with the metabolic syndrome1
|
|---|
|
Components of the Met. Syn.
|
Baseline
|
3 months
|
9 months
|
Reduction †
|
Baseline
|
3 months
|
9 months
|
Reduction †
|
|
Blood pressure
|
mean
|
± SD
|
mean
|
± SD
|
mean
|
± SD
| |
mean
|
± SD
|
mean
|
± SD
|
mean
|
± SD
| |
|
systolic
|
mmHg
|
159.1
|
± 12.9
|
137.8*
|
± 11.2
|
132.8*
|
± 10.1
|
-26.3
|
161.3
|
± 13.2
|
139.0*
|
± 11.2
|
133.8*
|
± 10.1
|
-27.5
|
|
diastolic
|
mmHg
|
93.4
|
± 8.6
|
82.8*
|
± 7.2
|
80.4*
|
± 6.6
|
-13.0
|
95.0
|
± 8.6
|
83.8*
|
± 7.4
|
80.9*
|
± 6.6
|
-14.1
|
|
Fasting plasma
| | | | | | | | | | | | | | | |
|
glucose
|
mg/dL
|
118.3
|
± 29.9
|
111.8*
|
± 26.0
|
109.9*
|
± 25.1
|
-8.4
|
122.9
|
± 29.8
|
115.4*
|
± 26.0
|
112.9*
|
± 24.7
|
-10.0
|
|
Abdominal obesity
| | | | | | | | | | | | | | | |
|
men
|
cm
|
109.9
|
± 13.0
|
108.4*
|
± 12.2
|
107.5*
|
± 11.9
|
-2.4
|
112.0
|
± 12.9
|
110.3*
|
± 12.3
|
108.8*
|
± 12.7
|
-3.2
|
|
women
|
cm
|
99.3
|
± 14.3
|
98.3*
|
± 14.3
|
98.1*
|
± 14.2
|
-1.2
|
101.5
|
± 14.7
|
100.8*
|
± 14.7
|
99.8*
|
± 14.4
|
-1.7
|
|
Triglycerides
|
mg/dL
|
212.3
|
± 61.2
|
194.2*
|
± 56.7
|
183.7*
|
± 52.1
|
-28.6
|
221.5
|
± 63.0
|
198.4*
|
± 55.3
|
187.4*
|
± 52.6
|
-34.1
|
|
HDL cholesterol
| | | | | | | | | | | | | | | |
|
men
|
mg/dL
|
42.2
|
± 7.7
|
44.6*
|
± 7.3
|
45.8*
|
± 7.2
|
3.6
|
41.4
|
± 7.5
|
44.0*
|
± 7.0
|
45.4*
|
± 6.8
|
4.0
|
|
women
|
mg/dL
|
45.0
|
± 7.2
|
47.8*
|
± 6.8
|
48.8*
|
± 6.5
|
3.8
|
44.2
|
± 7.4
|
46.4*
|
± 6.9
|
47.6*
|
± 6.8
|
3.4
|
- 1 doctors' diagnosis; statistical test applied: t-test; * p < 0.0001; ** p < 0.05; † reduction versus baseline
